Back to announcement
20260128_SDPC_Laporan Informasi dan Fakta Material_32022534_lamp1.pdf
Other Text extracted SDPCSource file signed link, expires in 15 minutes
Extracted text 2
Page 1 OCR 0.903
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk No. 1 078/MPI/DIR/1/2026 Jakarta, 28 January 2026 Lampiran : - Perihal 1 Laporan Informasi atau Fakta Material Yth. Kepala Eksekutif Pengawas Pasar Modal Otoritas Jasa Keuangan Gedung Soemitro Djojohadikusumo Jalan Lapangan Banteng Timur 2-4 Jakarta 10710 Sehubungan dengan Peraturan Otoritas Jasa Keuangan (OJK) no: 45 Tahun 2024 tanggal 31 Desember 2024 tentang Tentang Pengembangan dan Penguatan Emiten dan Perusahaan Publik, dengan ini kami menyampaikan Laporan Informasi atau Fakta Material sebagai berikut : In reference to Otoritas Jasa Keuangan (OJK) Regulation No.: 45 of 2024 dated 31 December 2024 regarding DDevelopment and Strengthening of Issuers and Public Companies, we hereby disclose the information and Material Fact as follow: Nama Emiten atau Perusahaan Publik//ssuer: PT Millennium Pharmacon International Tbk (“Perseroan”) Bidang Usaha/Scope of Business : Distribusi produk farmasi, suplemen makanan dan alat kesehatan Telepon/Phone 2 (021) 2708 5961, (021) 2708 5964 Faksimili/Facsimile 2 (021) 2708 5958 Alamat surat elektronik/e-mail 1. Investor.relation@mpi-pharmaniaga co.id 1 | Tanggal kejadian Date Event 27 January 2026 January 27", 2026 2 | Jenis Informasi atau Fakta Material Type of Information or Material Facts Penandatanganan Perubahan dan Penegasan | Signing of Amendments and Reaffirmation of Kembali Perjanjian Kredit Credit Agreements 3 | Uraian Informasi atau Fakta Material Description of Information or Material Facts a) Pihak-pihak yang melakukan perjanjian: | a) Parties to the agreement : Company and PT Perseroan dan PT Bank UOB Indonesia, Bank UOB Indonesia, b) Bank telah menyetujui perpanjangan | b) The Bank has approved the renewal of the fasilitas kredit dengan total limit sejumlah credit facilities with total limit facility Rp370 Miliar kepada Perseroan: amounted to 1DR370 billion to the company: c) Perubahan Jangka waktu perjanjian telah |'c) Changes the Agreement Period has been disetujui diperpanjang sampai dengan approved to be extended until January 29th, tanggal 29 Januari 2027, 2027. Crown Bungur Arteri 2-4th Floors Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia Phone : #6221 27085961
Page 2 OCR 0.930
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk Dampak kejadian, informasi atau fakta material tersebut terhadap kegiatan Operasional, hukum, kondisi keuangan, atau kelangsungan usaha Emiten atau Perusahaan Publik Fasilitas Kredit ini menunjang kegiatan usaha perseroan. Impact for such information or material fact towards operational activity, legal, financial condition or. business continuity of Issuer or Public Company This Credit Facility supports the company's business activities. Keterangan lain-lain Other Information Tidak ada None Hormat kami, PT Millennium Pharmacon International Tbk Nama: Moharhad Fazly Hassan Jabatan: Direktur Tembusan: PT Bursa Efek Indonesia Crown Bungur Arteri 2-4th Floors Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia Phone : 46221 27085961
Names mentioned 6 people and organisations named in the text · linked when the evidence is strong
unresolved
person
Nama: Moharhad Fazly Hassan
· Jabatan: Direktur
p.2
unresolved
org
PT Bursa Efek Indonesia Crown Bungur Arteri
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.